Popular stocks
Vale S.A.
NVIDIA
MicroAlgo
AppLovin
GameStop
Boeing
Alibaba
TAL Education
Shopify
Dell Technologies
Shares of other companies:
Microsoft: A Critical Point in Valuation Momentum
May 23, 2025
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
In today’s data-driven business landscape, the ability to accurately measure and optimize marketing efforts has become a critical competitive advantage. As marketing evolves,…
May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?
Trading is a very popular endeavor these days, and for good reason, as it is widely accessible and allows individuals to generate additional…
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
What defines a successful crypto expert? The amount of money earned, the number of luxury cars and international real estate? The presence of…
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
You can use electronic exchange services if you need to exchange the digital asset USDC ERC20 to Bank Transfer. It is not recommended…
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
Most investors who want to expand their investment options put their money in different asset types and industries across many areas in the…
PFE Stock News of Pfizer Inc. Stocktwits
Updated: May 24, 2025 (09:13)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 40 days where Pfizer Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Pfizer Inc..
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Pfizer stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Stocktwits of Pfizer Inc. (PFE)
May 24, 2025 (08:51) / "Motley Fool" (by Keith Speights)
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
Most people like to buy products when prices are cheaper. That's why you'll probably see lots of car dealers, furniture stores, and retailers advertising special sales during the Memorial Day weekend.However, many investors are leery of buying a stock that has fallen sharply. Why?
In Article Trend: Neutral
May 24, 2025 (08:11) / "Motley Fool" (by James Brumley)
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.
In Article Trend: Neutral
May 23, 2025 (20:09) / "Zacks Commentary" (by Zacks Equity Research)
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.
In Article Trend: Neutral
May 23, 2025 (20:02) / "Zacks Commentary" (by Zacks Equity Research)
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.
In Article Trend: Neutral
May 23, 2025 (12:16) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.
In Article Trend: Neutral
May 23, 2025 (11:57) / "Motley Fool" (by CFA)
Pfizer Stock Analysis: Buy, Sell, or Hold?
Pfizer's ( NYSE: PFE ) management team is confident in its 2025 opportunities.*Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.Continue reading ...
In Article Trend: Bearish
May 23, 2025 (00:15) / "GlobeNewswire" (by ASCENTAGE PHARMA GROUP INTERNATIONAL)
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma ( NASDAQ: AAPG. HKEX: 6855 ) , a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two ongoing investigational studies ...
In Article Trend: Neutral
May 22, 2025 (20:54) / "Benzinga" (by Globe Newswire)
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, May 22, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.
In Article Trend: Somewhat-Bullish
May 22, 2025 (14:48) / "Zacks Commentary" (by Zacks Equity Research)
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
In Article Trend: Neutral
May 22, 2025 (12:15) / "Benzinga" (by Avi Kapoor)
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Merck & Co ( NYSE:MRK ) , Pfizer ( NYSE:PFE )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
In Article Trend: Somewhat-Bullish
May 22, 2025 (11:42) / "Zacks Commentary" (by Rajani Lohia)
5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GDOT, JAKK, PCB, ROCK and PFE hold promise.
In Article Trend: Somewhat-Bullish
May 22, 2025 (01:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the Firm - GoHealth ( NASDAQ:GOCO ) , Arvinas ( NASDAQ:ARVN )
NEW YORK, May 21, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims Organon & Co. OGN, Landstar System, Inc. LSTR, Arvinas, Inc. ARVN, and GoHealth, Inc.
In Article Trend: Neutral
May 21, 2025 (13:08) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Pfizer, Coca-Cola and The Walt Disney
Pfizer, Coca-Cola and The Walt Disney are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
May 21, 2025 (12:37) / "Zacks Commentary" (by Sundeep Ganoria)
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
In Article Trend: Neutral
May 21, 2025 (10:42) / "Benzinga" (by Tanya Rawat)
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr. - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.
In Article Trend: Somewhat-Bullish
May 21, 2025 (10:23) / "Motley Fool" (by Prosper Junior Bakiny)
2 High-Yield Dividend Stocks to Buy Right Now
Though there are plenty of dividend stocks on the market, they aren't all created equal. Consider that the average dividend yield for the S&P 500 ( SNPINDEX: ^GSPC ) is 1.3%, which is not particularly high.Of course, there is more to income investing than chasing juicy yields.
In Article Trend: Neutral
May 21, 2025 (10:00) / "South China Morning Post" (by Xinmei Shen)
Chinese biotech firm secures Pfizer deal despite trade tensions
Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China's 3SBio.
In Article Trend: Neutral
May 21, 2025 (08:48) / "Motley Fool" (by Keith Speights)
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Resilient and growing. Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of what's happening with the economy. And with elderly populations increasing in many countries ( including the U.S. ) , the demand for healthcare ...
In Article Trend: Somewhat-Bullish
May 21, 2025 (04:00) / "Financial Times"
How Trump's tariffs threaten Ireland's pharma fortune
The pharma hub stands to lose a lot in the US president's second term ...
In Article Trend: Neutral
May 20, 2025 (20:34) / "CNBC"
Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.
In Article Trend: Somewhat-Bullish
May 20, 2025 (19:10) / "Benzinga" (by Vaishali Prayag)
What's Going On With Vaccine Stocks Today? - BioNTech ( NASDAQ:BNTX )
Vaccine stocks are rising after the FDA announced it will consider updating COVID-19 vaccines to target the rapidly spreading LP.8.1. The FDA will require new clinical trials for annual boosters in healthy people under 65, limiting this fall's shots.
In Article Trend: Somewhat-Bullish
May 20, 2025 (17:00) / "Benzinga" (by Benzinga Insights)
P/E Ratio Insights for Pfizer - Pfizer ( NYSE:PFE )
Looking into the current session, Pfizer Inc. PFE shares are trading at $23.35, after a 1.52% increase. Moreover, over the past month, the stock spiked by 3.64%, but in the past year, decreased by 21.11%.
In Article Trend: Neutral
May 20, 2025 (16:50) / "Benzinga" (by Adam Eckert)
Pfizer Stock Is Trading Higher Tuesday: What's Going On? - Pfizer ( NYSE:PFE )
FDA advisors are planning to discuss if they should recommend COVID-19 vaccines for 2025-26 targeting the LP.8.1 subvariant. Pfizer announces a licensing agreement with 3SBio to develop, manufacture and commercialize SSGJ-707 globally, excluding China.
In Article Trend: Somewhat-Bullish
May 20, 2025 (16:00) / "Benzinga" (by Benzinga Insights)
How Do Investors Really Feel About Pfizer? - Pfizer ( NYSE:PFE )
Pfizer's PFE short percent of float has risen 6.84% since its last report. The company recently reported that it has 115.16 million shares sold short, which is 2.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.35 days to cover their ...
In Article Trend: Somewhat-Bullish
May 20, 2025 (14:22) / "Zacks Commentary" (by Zacks Equity Research)
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.
In Article Trend: Neutral
May 20, 2025 (13:00) / "Benzinga" (by Globe Newswire)
Alation Acquires Numbers Station to Unlock a New Era of Agentic Workflows
REDWOOD CITY, Calif., May 20, 2025 ( GLOBE NEWSWIRE ) -- Alation Inc., the leader in enterprise data intelligence, today announced that it has acquired Numbers Station AI, a pioneer in building AI agents for data workflows.
In Article Trend: Somewhat-Bullish
May 20, 2025 (13:00) / "Zacks Commentary" (by Zacks Investment Research)
Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential
Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.
In Article Trend: Somewhat-Bullish
May 20, 2025 (12:46) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
In Article Trend: Somewhat-Bullish
May 20, 2025 (10:28) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.
In Article Trend: Neutral
May 20, 2025 (07:50) / "Motley Fool" (by David Jagielski)
These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safe
If you see a stock that pays 6% in dividends, you might assume it's too risky -- but that's not always the case. In some situations, a yield can grow to such heights because investors have been dumping the stock. This can occur due to concerns around a company's business, including poor financial ...
In Article Trend: Neutral
May 20, 2025 (03:55) / "Benzinga" (by Kaustubh Bagalkote)
Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal - Pfizer ( NYSE:PFE )
Pfizer Inc. PFE announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707 in a deal potentially worth up to $6 billion. The agreement includes a $1.25 billion upfront payment to the Chinese biopharmaceutical company, with additional ...
In Article Trend: Somewhat-Bullish
May 20, 2025 (00:00) / "Benzinga" (by Globe Newswire)
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, May 19, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.
In Article Trend: Somewhat-Bullish
May 19, 2025 (21:59) / "Benzinga" (by Globe Newswire)
Cerevel Therapeutics Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025 Deadline to file Lead Plaintiff Motion
LOS ANGELES, May 19, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) CERE investors of a class action representing investors that bought securities between October 11, 2023 through August 1, 2024, inclusive ( the "Class ...
In Article Trend: Neutral
May 19, 2025 (14:35) / "Benzinga" (by Akanksha Bakshi)
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment - Novavax ( NASDAQ:NVAX ) , Sanofi ( NASDAQ:SNY )
Novavax Inc. NVAX has received limited approval from the U.S. Food and Drug Administration for its COVID-19 vaccine, Nuvaxovid, marking a regulatory milestone and unlocking a $175 million milestone payment from partner Sanofi SA SNY. The protein-based vaccine, distinct from mRNA options by Pfizer ...
In Article Trend: Somewhat-Bullish
May 19, 2025 (13:42) / "Zacks Commentary" (by Zacks Equity Research)
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
In Article Trend: Neutral
May 19, 2025 (12:31) / "GlobeNewswire" (by Inc.)
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively.
In Article Trend: Somewhat-Bullish
May 19, 2025 (12:31) / "Benzinga" (by Globe Newswire)
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition - Prime Medicine ( NASDAQ:PRME )
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively.
In Article Trend: Somewhat-Bullish
May 19, 2025 (12:30) / "Benzinga" (by Globe Newswire)
Madison Realty Capital Originates $720 Million Loan for Office-to-Residential Conversion of Former Pfizer Headquarters - Marcus & Millichap ( NYSE:MMI )
NEW YORK, May 19, 2025 ( GLOBE NEWSWIRE ) -- Madison Realty Capital, a vertically integrated real estate private equity firm focused on real estate private credit, today announced that it has originated a $720 million loan to a joint-venture between Metro Loft Developers and David Werner Real ...
In Article Trend: Somewhat-Bullish
May 19, 2025 (12:29) / "Zacks Commentary" (by Kinjel Shah)
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
Both PFE and MRK have strong product and pipeline portfolios in oncology.
In Article Trend: Neutral
May 19, 2025 (12:00) / "Benzinga" (by Globe Newswire)
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value - Keros Therapeutics ( NASDAQ:KROS ) , Takeda Pharmaceutical Co ( NYSE:TAK )
Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting "FOR" Each of the Company's Highly Qualified Director Nominees
In Article Trend: Somewhat-Bullish
May 19, 2025 (11:00) / "GlobeNewswire" (by Iterum Therapeutics PLC)
Iterum Therapeutics Announces Extension of Term of Promissory Note
DUBLIN and CHICAGO, May 19, 2025 ( GLOBE NEWSWIRE ) -- Iterum Therapeutics plc ( Nasdaq: ITRM ) ( the "Company" or "Iterum" ) , a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital ...
In Article Trend: Somewhat-Bullish
May 19, 2025 (11:00) / "Benzinga" (by Globe Newswire)
Iterum Therapeutics Announces Extension of Term of Promissory Note - Iterum Therapeutics ( NASDAQ:ITRM )
DUBLIN and CHICAGO, May 19, 2025 ( GLOBE NEWSWIRE ) -- Iterum Therapeutics plc ITRM ( the "Company" or "Iterum" ) , a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today ...
In Article Trend: Somewhat-Bullish
May 19, 2025 (08:39) / "Benzinga" (by Tanya Rawat)
Novavax Wins Limited FDA Nod For COVID Shot-Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny - Novavax ( NASDAQ:NVAX ) , BioNTech ( NASDAQ:BNTX )
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s NVAX COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase the risk of severe illness.
In Article Trend: Neutral
May 18, 2025 (16:05) / "Motley Fool" (by Collin Brantmeyer)
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Here are three dividend-paying stocks that warrant closer examination.
In Article Trend: Neutral
May 16, 2025 (20:00) / "Benzinga" (by Globe Newswire)
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or "the Company" ) CERE, Bain Capital ...
In Article Trend: Neutral
May 16, 2025 (15:26) / "Benzinga" (by Globe Newswire)
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) ( NASDAQ: CERE ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) CERE for violations of the federal ...
In Article Trend: Neutral
May 16, 2025 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer Inc. ( PFE ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
May 16, 2025 (08:49) / "Motley Fool" (by Keith Speights)
Here's How Many Shares of Pfizer You Should Own to Make $10,000 in Annual Dividend Income
Looking for income? You might want to check out Pfizer ( NYSE: PFE ) . This big drugmaker has been a favorite for income investors for years. However, its dividend is arguably more attractive than ever. At this writing, the forward dividend yield stands at a mouthwatering 7.52%.The more you ...
In Article Trend: Bullish
May 16, 2025 (08:47) / "Motley Fool" (by Keith Speights)
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
Bad news keeps coming for Novo Nordisk ( NYSE: NVO ) . The Denmark-based drugmaker's share price has plunged roughly 55% below its high set last summer. Earlier this week, a study published in The New England Journal of Medicine revealed that patients taking Eli Lilly's Zepbound lost more weight ...
In Article Trend: Somewhat-Bullish
May 15, 2025 (13:59) / "Benzinga" (by Sandeep Gupta)
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025 - Johnson & Johnson ( NYSE:JNJ ) , AbbVie ( NYSE:ABBV )
Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen acquisition.
In Article Trend: Somewhat-Bullish
May 15, 2025 (12:36) / "Zacks Commentary" (by Kinjel Shah)
5 Low Price-to-Book Value Stocks to Buy in May
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
In Article Trend: Somewhat-Bullish
May 15, 2025 (09:57) / "Motley Fool" (by Cory Renauer)
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Recently, the Trump Administration signed an executive order to lower the prices Americans pay for prescription drugs. According to the administration, the U.S. funds roughly 75% of global pharmaceutical profits despite having less than 5% of the population.It's no secret that brand-name drugs in ...
In Article Trend: Neutral
May 14, 2025 (22:05) / "Motley Fool" (by James Brumley)
3 Magnificent S&P 500 Dividend Stocks Down 62%, 63%, and 64% to Buy and Hold Forever
Temporary turbulence has resulted in opportunity for patient, bargain-hunting investors.
In Article Trend: Somewhat-Bullish
May 14, 2025 (19:58) / "Benzinga" (by Vandana Singh)
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 - Sanofi ( NASDAQ:SNY )
Sanofi to invest $20 billion in the US by 2030, boosting R&D and expanding domestic manufacturing capacity. Investment aims to create high-paying jobs and strengthen the US supply chain through partnerships and facility growth.
In Article Trend: Somewhat-Bullish
May 14, 2025 (13:30) / "GlobeNewswire" (by Inc.)
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
SAN FRANCISCO, May 14, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company's ongoing ...
In Article Trend: Neutral
May 14, 2025 (11:30) / "GlobeNewswire" (by Arbutus Biopharma Corporation)
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B ( cHBV ) to date, including 2 patients who received no interferon ...
In Article Trend: Neutral
May 14, 2025 (11:30) / "GlobeNewswire" (by LAVA Therapeutics N.V.)
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 ( GLOBE NEWSWIRE ) -- LAVA Therapeutics N.V. ( NASDAQ: LVTX, "LAVA," "the Company" ) , a clinical-stage immuno-oncology company focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced recent corporate ...
In Article Trend: Neutral
May 13, 2025 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
PFE vs. LLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer ( PFE Quick QuotePFE - ) and Eli Lilly ( LLY Quick QuoteLLY - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
In Article Trend: Bullish
May 13, 2025 (14:37) / "Zacks Commentary" (by Sumit Singh)
4 Value Picks to Ride the Market Rebound After US-China Trade Thaw
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio.
In Article Trend: Somewhat-Bullish
May 13, 2025 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Should Value Investors Buy Pfizer ( PFE ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In Article Trend: Somewhat-Bullish
May 13, 2025 (13:23) / "Benzinga" (by David Pinsen)
Even Pharma Rallied On Monday - SPDR Select Sector Fund - Health Care ( ARCA:XLV )
Join Plus500 today and get up to $200 to start trading real futures. Practice with free paper trading, then jump into live markets with lightning-fast execution, low commissions, and full regulatory protection.
In Article Trend: Neutral
May 13, 2025 (13:22) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen
J&J, Eli Lilly, Pfizer, Merck, Amgen are included in this Analyst Blog.
In Article Trend: Neutral
May 13, 2025 (13:09) / "Benzinga" (by Avi Kapoor)
Jim Cramer Is 'OK' With Harrow, Recommends This Energy Stock - Devon Energy ( NYSE:DVN ) , Energy Transfer ( NYSE:ET )
When asked about Iron Mountain, Cramer said, "No, better places to be." Get our list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on. On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Energy Transfer LP ET. "The pipes are a great ...
In Article Trend: Bullish
May 13, 2025 (13:00) / "Zacks Commentary" (by Andrew Rocco)
US-China Talks Spark Optimism; Betting Markets See Recession Odds Drop
A surprising thaw in US-China trade relations sparked significant optimism on Wall Street Monday. This positive development, coupled with lower recession odds, sets up a bullish long-term outlook for investors.
In Article Trend: Neutral
May 13, 2025 (11:36) / "Zacks Commentary" (by Kinjel Shah)
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.
In Article Trend: Neutral
May 13, 2025 (09:00) / "Benzinga" (by Globe Newswire)
JD.com Announces First Quarter 2025 Results - JD.com ( NASDAQ:JD )
BEIJING, May 13, 2025 ( GLOBE NEWSWIRE ) -- JD.com, Inc. JD and 89618 ( RMB counter ) , the "Company" or "JD.com" ) , a leading supply chain-based technology and service provider, today announced its unaudited financial results for the three months ended March 31, 2025.
In Article Trend: Somewhat-Bullish
May 13, 2025 (09:00) / "GlobeNewswire" (by Inc.)
JD.com Announces First Quarter 2025 Results
BEIJING, May 13, 2025 ( GLOBE NEWSWIRE ) -- JD.com, Inc. ( NASDAQ: JD and HKEX: 9618 ( HKD counter ) and 89618 ( RMB counter ) , the "Company" or "JD.com" ) , a leading supply chain-based technology and service provider, today announced its unaudited financial results for the three months ended ...
In Article Trend: Somewhat-Bullish
May 12, 2025 (19:54) / "CNBC"
Trump wants to slash U.S. drug prices with 'most favored nation' policy - here's what to know
Health policy experts said it is still unclear how much prices will go down, which medicines will be impacted and whether the effort can be implemented at all.
In Article Trend: Neutral
May 12, 2025 (15:50) / "Benzinga" (by David Pinsen)
Profiting From A Pharma Panic
Executive orders often move markets before move policy is implemented. Late Sunday, President Trump said he'll sign a Most‑Favored‑Nation ( MFN ) order forcing U.S. payers to match the lowest price any country gets for each prescription drug.
In Article Trend: Neutral
May 12, 2025 (13:37) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
In Article Trend: Neutral
May 12, 2025 (12:54) / "CNBC"
Trump to sign order to cut some U.S. drug prices to match those abroad
The order is a blow to the pharmaceutical industry, which is already bracing for Trump's planned tariffs on prescription drugs.
In Article Trend: Neutral
May 12, 2025 (12:51) / "CNBC"
Jim Cramer's top 10 things to watch in the stock market Monday
Stocks are soaring after the U.S. and China agreed to temporarily slash their tariff rates.
In Article Trend: Neutral
May 12, 2025 (12:50) / "Zacks Commentary" (by Zacks Investment Research)
Zacks Market Edge Highlights: WHR, PFE, CVX, CC and DOW
WHR, PFE, CVX, CC and DOW have been highlighted in this Market Edge article.
In Article Trend: Neutral
May 12, 2025 (12:30) / "GlobeNewswire" (by Biodexa Pharmaceuticals PLC)
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
May ...
In Article Trend: Neutral
May 12, 2025 (11:40) / "Benzinga" (by Namrata Sen)
Mark Cuban Challenges Charlie Kirk's Take On Big Pharma, Highlights Role Of PBMs In Drug Price Surge: 'For Your Company…Ask Your PBM For A List Of Claims' - Johnson & Johnson ( NYSE:JNJ ) , Eli Lilly ( NYSE:LLY )
Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers ( PBMs ) are the main culprits, not Big Pharma.
In Article Trend: Neutral
May 12, 2025 (08:51) / "Motley Fool" (by Keith Speights)
Wondering if Pfizer's 7.6% Dividend Yield Is Sustainable? Here's What You Need to Know.
Income investors have liked Pfizer ( NYSE: PFE ) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive.But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty.
In Article Trend: Neutral
May 12, 2025 (08:32) / "Benzinga" (by Vishaal Sanjay)
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket - Amgen ( NASDAQ:AMGN ) , Bristol-Myers Squibb ( NYSE:BMY )
On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices. What Happened: Trump said the executive order, set to be signed at 9 a.m.
In Article Trend: Neutral
May 12, 2025 (07:00) / "Benzinga" (by Globe Newswire)
Alation Launches Data Products Builder Agent to Power AI-Ready Data
LONDON, May 12, 2025 ( GLOBE NEWSWIRE ) -- Alation Inc., the data intelligence company, today announced the launch of its Data Products Builder Agent, an AI-powered tool that helps data teams turn messy, raw data into trusted, reusable data products.
In Article Trend: Somewhat-Bullish
May 12, 2025 (05:00) / "GlobeNewswire" (by VALNEVA)
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Saint Herblain ( France ) , May, 12 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced that the U.S. Food and Drug Association ( FDA ) and the U.S. Centers for Disease Control and Prevention ( CDC ) , in a joint communication to the medical ...
In Article Trend: Neutral
May 12, 2025 (05:00) / "Benzinga" (by Globe Newswire)
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Saint Herblain ( France ) , May, 12 2025 - Valneva SE VALNVLA, a specialty vaccine company, today announced that the U.S. Food and Drug Association ( FDA ) and the U.S.
In Article Trend: Neutral
May 12, 2025 (02:19) / "Benzinga" (by Ananya Gairola)
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency' - iShares U.S. Pharmaceutical ETF ( ARCA:IHE ) , Johnson & Johnson ( NYSE:JNJ )
On Sunday, President Donald Trump vowed to slash prescription drug prices through a sweeping executive order. What Happened: Trump took to Truth Social and announced plans to sign a new executive order.
In Article Trend: Somewhat-Bullish
May 11, 2025 (12:29) / "Benzinga" (by Globe Newswire)
Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - CERE
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options
In Article Trend: Neutral
May 11, 2025 (01:40) / "Benzinga" (by PRNewswire)
Ellis Island Honors Society Presents the 2025 Ellis Island Medals of Honor
Leaders in business, education, entertainment, public service, philanthropy, media, healthcare, sports, and the defense of the United Stateshonored with the prestigious Ellis Island Medals of HonorDuring Gala on Ellis Island **** Her Majesty Queen Silvia of Sweden,Receives Global Humanitarian ...
In Article Trend: Bullish
May 10, 2025 (09:39) / "Motley Fool" (by Rick Munarriz)
3 Magnificent S&P 500 Dividend Stocks Down 30% to Buy and Hold Forever
These household names and index components are yielding better than 4.5% with compelling valuations.
In Article Trend: Somewhat-Bullish
May 9, 2025 (19:01) / "Benzinga" (by Benzinga Insights)
This Is What Whales Are Betting On Pfizer - Pfizer ( NYSE:PFE )
Investors with significant funds have taken a bullish position in Pfizer PFE, a development that retail traders should be aware of. This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga.
In Article Trend: Somewhat-Bullish
May 9, 2025 (17:26) / "Benzinga" (by James Gornick)
New FDA Leadership Could Raise The Bar For Drug Approvals
New FDA Leadership Team: The FDA's top leadership has shifted under Commissioner Dr. Marty Makary, with Dr. Vinayak "Vinay" Prasad now heading the Center for Biologics Evaluation and Research ( CBER ) and Dr. Sanjula Jain-Nagpal serving as Associate Director of Policy & Research Strategy in the ...
In Article Trend: Somewhat-Bullish
May 9, 2025 (16:44) / "Zacks Commentary" (by Tracey Ryniec)
Are Your Mega-High Stock Dividends Safe?
Tracey Ryniec, Zacks Senior Stock Strategist, and Bryan Hayes, editor of Zacks Income Investor newsletter, discuss 5 popular stocks with high dividend yields. Can the dividend be trusted?
In Article Trend: Neutral
May 9, 2025 (14:31) / "Benzinga" (by Globe Newswire)
Generic Drugs Market size is projected to reach USD 594.99 billion by 2031, With growing at a CAGR of 5.0% | The Insight Partners
US & Canada, May 09, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the global Generic Drugs Market is growing owing to patent expiry and loss of market exclusivity, along with increasing government initiatives to promote the use of generic drugs.
In Article Trend: Neutral
May 9, 2025 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Just Overtook the 20-Day Moving Average
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
In Article Trend: Somewhat-Bullish
May 9, 2025 (12:12) / "Zacks Commentary" (by Rajani Lohia)
5 Low Price-to-Sales Stocks That Deserve a Place in Your Portfolio
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.
In Article Trend: Somewhat-Bullish
May 8, 2025 (20:23) / "GlobeNewswire" (by Inc.)
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
HUNTSVILLE, May 08, 2025 ( GLOBE NEWSWIRE ) -- Serina Therapeutics, Inc. ( "Serina" ) ( NYSE American: SER ) , a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, ...
In Article Trend: Somewhat-Bullish
May 8, 2025 (16:08) / "Benzinga" (by Chandrima Sanyal)
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks 3 Pharma ETFs To Watch As Trump Turns Up The Heat On Drugmakers - AstraZeneca ( NASDAQ:AZN ) , iShares U.S. Pharmaceutical ETF ( ARCA:IHE )
Trump's push to tie Medicaid drug prices to lower international benchmarks could erase $1 trillion in revenues over 10 years. Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on.
In Article Trend: Neutral
May 8, 2025 (15:50) / "Zacks Commentary" (by Sweta Killa)
A Look at Pharma ETFs After Strong Q1 Earnings
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
In Article Trend: Somewhat-Bullish
May 8, 2025 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
Can Pfizer ( PFE ) Climb 25.14% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Pfizer (PFE) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
In Article Trend: Somewhat-Bullish
May 8, 2025 (09:45) / "Motley Fool" (by David Jagielski)
Want $3,100 in Annual Dividends? Invest $18,000 in Each of These 3 Stocks
The average stock on the S&P 500 yields just 1.4%. If you invested $54,000 into stocks averaging that kind of a yield, you'd collect just $756 in annual dividend income. But if you invested that same amount, spread across the three high-yielding stocks listed below, your dividend income could ...
In Article Trend: Somewhat-Bullish
May 7, 2025 (15:45) / "GlobeNewswire" (by VALNEVA)
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
Saint Herblain ( France ) , May, 07 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced that the European Medicines Agency ( EMA ) has started a review of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® based on reports of ...
In Article Trend: Neutral
May 7, 2025 (15:45) / "Benzinga" (by Globe Newswire)
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
Saint Herblain ( France ) , May, 07 2025 - Valneva SE VALNVLA, a specialty vaccine company, today announced that the European Medicines Agency ( EMA ) has started a review of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® based on reports of serious adverse events ( SAEs ) in ...
In Article Trend: Neutral
May 7, 2025 (14:42) / "Benzinga" (by Globe Newswire)
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) ( NASDAQ: CERE ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, May 07, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) CERE for violations of the federal ...
In Article Trend: Neutral
May 7, 2025 (13:56) / "Benzinga" (by Vandana Singh)
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Virtus LifeSci Biotech Clinical Trials ETF ( ARCA:BBC ) , Capricor Therapeutics ( NASDAQ:CAPR )
Virtus BBC ETF fell 9.74% to $17.15; SPDR XBI ETF dropped 6.63% to $77.17 on Tuesday. William Blair says Moderna faces increased scrutiny with mRNA vaccines under new CBER leadership. Get prepared for the Fed's next move-live with Matt Maley on Wednesday, May 7 at 6 PM ET. Reserve your free spot ...
In Article Trend: Neutral
May 7, 2025 (06:01) / "GlobeNewswire" (by Arbutus Biopharma Corporation)
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver ( EASL ) Congress 2025
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B ( cHBV ) patients when combined with VTP-300 and low dose ...
In Article Trend: Neutral
May 7, 2025 (05:00) / "Benzinga" (by Globe Newswire)
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024 Cash and cash equivalents of €153.0 million at end of March 2025
In Article Trend: Neutral
May 7, 2025 (05:00) / "GlobeNewswire" (by VALNEVA)
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Saint-Herblain ( France ) , May 7, 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance.
In Article Trend: Neutral
May 6, 2025 (22:15) / "Motley Fool" (by Eric Volkman)
Why BioNTech Stock Got Trounced on Tuesday
An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech ( NASDAQ: BNTX ) . Investors were concerned about the latest top-level appointment in public health, plus an analyst became a bit more bearish about the company's ...
In Article Trend: Neutral
May 6, 2025 (19:21) / "Benzinga" (by Vandana Singh)
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight - Becton Dickinson ( NYSE:BDX ) , Bristol-Myers Squibb ( NYSE:BMY )
FDA conducts 12K domestic inspections yearly, but only 3K abroad-foreign sites flagged for serious issues over twice as often. Johnson & Johnson, Roche, and Novartis plan over $128 billion in combined U.S. investments over the next five years.
In Article Trend: Neutral
May 6, 2025 (17:15) / "Benzinga" (by PRNewswire)
The WNET Group Names Randall T. Decker Senior Director, Technology
NEW YORK, May 6, 2025 /PRNewswire/ -- The WNET Group, parent company of America's flagship PBS station THIRTEEN, announced the appointment of Randall T. Decker to Senior Director, Technology, effective immediately. Decker will oversee Infrastructure and Production Technology, as well as ...
In Article Trend: Bullish
May 6, 2025 (13:54) / "Zacks Commentary" (by Zacks Equity Research)
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
In Article Trend: Neutral
May 6, 2025 (08:33) / "Motley Fool" (by Eric Volkman)
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' ( NASDAQ: VKTX ) stock in April. Another was a looming late-stage clinical trial of a closely watched pipeline drug ...
In Article Trend: Somewhat-Bullish
May 6, 2025 (00:00) / "Benzinga" (by Globe Newswire)
Kirby McInerney LLP Announces Investigation of Potential Claims Against Arvinas, Inc. ( ARVN ) on Behalf of Investors - Arvinas ( NASDAQ:ARVN )
NEW YORK , May 05, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arvinas, Inc. ( "Arvinas" or the "Company" ) ARVN. The investigation concerns whether Arvinas and/or certain of its officers have violated the federal securities laws.
In Article Trend: Somewhat-Bullish
May 5, 2025 (21:57) / "CNBC"
Hinge Health says revenue increased 50% in first quarter - still no price range for IPO
Hinge Health on Monday updated its prospectus to include the results from its first quarter, which showed accelerating revenue growth over its fourth quarter. The digital physical therapy startup filed to go public in March, but it has not shared a price range yet.
In Article Trend: Neutral
May 5, 2025 (20:56) / "CNBC"
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms
The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.
In Article Trend: Neutral
May 5, 2025 (19:49) / "Benzinga" (by Vandana Singh)
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion - BioNTech ( NASDAQ:BNTX )
BioNTech reported Q1 revenue of $192.23 million, surpassing the consensus of $177.40 million. Cash and investments totaled 15.85 billion euros as of March 31, 2025. Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on.
In Article Trend: Somewhat-Bullish
May 5, 2025 (19:39) / "Benzinga" (by Globe Newswire)
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, May 05, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.
In Article Trend: Somewhat-Bullish
May 5, 2025 (16:00) / "CNBC"
Function Health buys Ezra, launches full-body scan for a third of the price
Function Health on Monday announced it has acquired the full-body MRI scanning company Ezra ...
In Article Trend: Neutral
May 5, 2025 (13:13) / "Zacks Commentary" (by Ahan Chakraborty)
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
In Article Trend: Somewhat-Bullish
May 5, 2025 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer Inc. ( PFE ) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
May 5, 2025 (12:22) / "Zacks Commentary" (by Anindya Barman)
Top Wide-Moat Stocks to Invest in for Long-Term Growth
Investing in wide-moat stocks like PFE, ASML, LRCX and KO can be a strategy for long-term wealth creation due to their ability to deliver consistent returns.
In Article Trend: Bullish
May 5, 2025 (12:10) / "Zacks Commentary" (by Kinjel Shah)
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
Investors may stay invested in PFE stock to see how its new growth drivers perform.
In Article Trend: Neutral
May 5, 2025 (10:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
Conference call and webcast scheduled for May 5, 2025, at 8:00 a.m. EDT ( 2:00 p.m. CEST ...
In Article Trend: Neutral
May 5, 2025 (10:30) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
Mainz, Germany, May 5, 2025 ( GLOBE NEWSWIRE ) - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer ( "CFO" ) effective July 1, 2025.
In Article Trend: Somewhat-Bullish
May 2, 2025 (15:55) / "Motley Fool" (by Rich Smith)
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.
In Article Trend: Neutral
May 2, 2025 (14:00) / "Benzinga" (by Globe Newswire)
Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research®
Lewes, Delaware, May 02, 2025 ( GLOBE NEWSWIRE ) -- The Global Liver Cancer Treatment Market Size is projected to grow at a CAGR of 13.45% from 2024 to 2031, according to a new report published by Verified Market Research®.
In Article Trend: Neutral
May 2, 2025 (13:01) / "Zacks Commentary" (by Zacks Equity Research)
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
In Article Trend: Somewhat-Bullish
May 2, 2025 (08:20) / "Motley Fool" (by Justin Pope)
Where Will Viking Therapeutics Be in 3 Years?
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
In Article Trend: Neutral
May 2, 2025 (07:51) / "Motley Fool" (by Sean Williams)
3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May
Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' pocketbooks.
In Article Trend: Somewhat-Bullish
May 1, 2025 (21:44) / "Benzinga" (by Globe Newswire)
BREAKING: Block & Leviton Investigating Arvinas, Inc. ( ARVN ) For Securities Fraud After Shares Fall Over 20%; Investors Encouraged to Contact the Firm to Potentially Recover Losses - Arvinas ( NASDAQ:ARVN )
BOSTON, May 01, 2025 ( GLOBE NEWSWIRE ) -- Block & Leviton is investigating Arvinas, Inc. ARVN for potential securities law violations. Investors who have lost money in their Arvinas, Inc. investment should contact the firm to learn more about how they might recover those losses.
In Article Trend: Neutral
May 1, 2025 (16:43) / "Zacks Commentary" (by Zacks Equity Research)
OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands
Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.
In Article Trend: Neutral
May 1, 2025 (15:51) / "Zacks Commentary" (by Zacks Equity Research)
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates. Stock declines.
In Article Trend: Neutral
May 1, 2025 (15:42) / "Benzinga" (by Globe Newswire)
Gene Therapy Momentum Builds Among Hematologists in Sickle Cell Disease Management Despite Ongoing Access Barriers, According to Spherix Global Insights
EXTON, PA, May 01, 2025 ( GLOBE NEWSWIRE ) -- Patients with sickle cell disease ( SCD ) continue to face severe complications, despite advances in treatment that have helped mitigate some risks.
In Article Trend: Somewhat-Bullish
May 1, 2025 (13:11) / "CNBC"
Eli Lilly CEO says company can help 'respond' to national security concerns around essential drugs as tariffs loom
Ricks said reshoring manufacturing capacity for older essential medicines is "a valid thing," adding that Eli Lilly is "happy to help." ...
In Article Trend: Neutral
May 1, 2025 (12:45) / "GlobeNewswire" (by Akari Therapeutics Plc)
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products ...
In Article Trend: Somewhat-Bullish
May 1, 2025 (12:45) / "Benzinga" (by Globe Newswire)
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology - Akari Therapeutics ( NASDAQ:AKTX )
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage
In Article Trend: Somewhat-Bullish
May 1, 2025 (12:40) / "Zacks Commentary" (by Sanghamitra Saha)
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Top-ranked stocks Fox (FOXA), Universal Technical Institute (UTI), Pfizer (PFE), Tenet Healthcare (THC) and Newmont (NEM) are likely to beat on the bottom line in their upcoming releases.
In Article Trend: Somewhat-Bullish
May 1, 2025 (12:00) / "Business Insider" (by markets.businessinsider.com)
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran ...
In Article Trend: Somewhat-Bullish
May 1, 2025 (12:00) / "Benzinga" (by Globe Newswire)
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - Vaxcyte ( NASDAQ:PCVX )
SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc.
In Article Trend: Somewhat-Bullish
May 1, 2025 (12:00) / "GlobeNewswire" (by Inc.)
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran ...
In Article Trend: Neutral
May 1, 2025 (11:00) / "GlobeNewswire" (by Ligand Pharmaceuticals)
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 01, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) today announced that its senior management team will participate in the following upcoming investor conferences: • H.C. Wainwright Royalty Company Conference ( Virtual ) .
In Article Trend: Somewhat-Bullish
May 1, 2025 (11:00) / "Benzinga" (by Globe Newswire)
Ligand to Participate in May Investor Conferences - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., May 01, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference ( Virtual ) .
In Article Trend: Somewhat-Bullish
May 1, 2025 (11:00) / "GlobeNewswire" (by Arvinas Inc.)
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings ...
In Article Trend: Neutral
May 1, 2025 (08:15) / "Motley Fool" (by James Brumley)
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks.
There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight.
In Article Trend: Neutral
April 30, 2025 (20:29) / "Benzinga" (by Vandana Singh)
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing - Pfizer ( NYSE:PFE )
Pfizer reaffirmed $10-$15 billion for business development, with focus on immunology and cardiometabolic expansion. CEO Bourla says national security concerns are central to U.S. drug manufacturing strategy, not tariffs alone. Don't face extreme market conditions unprepared.
In Article Trend: Somewhat-Bullish
April 30, 2025 (20:12) / "CNBC"
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
In Article Trend: Neutral
April 30, 2025 (16:42) / "CNBC"
RFK Jr. is gutting minority health offices across HHS that are key to reducing health disparities
The cuts have hit most of the eight minority health offices across HHS, in many cases laying off the majority of workers, if not all of them, sources said.
In Article Trend: Neutral
April 30, 2025 (14:00) / "Benzinga" (by PRNewswire)
ELLIS ISLAND HONORS SOCIETY ANNOUNCES THE 2025 ELLIS ISLAND MEDALS OF HONOR RECIPIENTS
Leaders in business, education, entertainment, public service, philanthropy, media, healthcare, sports, and the defense of the United States to be honored with the prestigious Ellis Island Medals of Honor on May 10th During Gala on Ellis Island
In Article Trend: Bullish
April 30, 2025 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Company News for Apr 30, 2025
Companies In The News Are: NUE, REGN, PYPL, PFE.
In Article Trend: Somewhat-Bullish
April 30, 2025 (13:08) / "Zacks Commentary" (by Kinjel Shah)
Boost Your Portfolio With These 5 Low Price-to-Book Stocks
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, MD, PFE, STNE and SAN are some such stocks.
In Article Trend: Somewhat-Bullish
April 30, 2025 (11:05) / "Motley Fool" (by David Jagielski)
Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul
Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year. And that's after recovering recently -- it was down much more than that in early April when global tariffs were first announced.
In Article Trend: Somewhat-Bullish
April 30, 2025 (10:45) / "Motley Fool" (by George Budwell)
This High-Yield Pharma Stock Looks Like an Incredible Bargain
When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of economic conditions.One big pharma name stands out as an exceptional opportunity: Bristol Myers Squibb ...
In Article Trend: Somewhat-Bullish
April 30, 2025 (10:15) / "Motley Fool" (by David Jagielski)
Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?
When a stock yields more than 5%, investors start to become skeptical about whether the payout is indeed safe. While it's tempting to want to believe that it can be safe and that it can be an excellent source of future dividend income, you also don't want to get burned and see that dividend get ...
In Article Trend: Neutral
April 30, 2025 (10:06) / "Benzinga" (by Vishaal Sanjay)
US Stock Futures Fall After Tuesday Rally, But History Favors Bulls: Markets Rose 9 Of Last 10 Mays, Says Expert - Caterpillar ( NYSE:CAT ) , Domino's Pizza ( NASDAQ:DPZ )
U.S. stock futures declined Wednesday morning, even as major indexes closed higher on Tuesday, with the S&P 500 and Dow Jones logging their sixth consecutive day of gains - marking their longest winning streak in months.
In Article Trend: Somewhat-Bullish
April 30, 2025 (08:51) / "Motley Fool" (by Keith Speights)
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs. Other drugmakers are eyeing the market as well.Pfizer ( NYSE: PFE ) is certainly in ...
In Article Trend: Neutral
April 30, 2025 (08:33) / "Zacks Commentary" (by Sanghamitra Saha)
Is Healthcare Losing the Status of Safe Haven? ETFs in Focus
Healthcare stocks face new risks under Trump, despite their usual defensive reputation.
In Article Trend: Neutral
April 30, 2025 (08:31) / "Benzinga" (by Avi Kapoor)
Dow Surges 300 Points Amid Trade Deal Hopes: Greed Index Remains In 'Fear' Zone - Coca-Cola ( NYSE:KO ) , Caterpillar ( NYSE:CAT )
The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the "Fear" zone on Tuesday. U.S. stocks settled higher on Tuesday, with the Dow Jones index gaining 300 points during the session on indications that the United States was nearing a ...
In Article Trend: Neutral
April 30, 2025 (07:15) / "Motley Fool" (by Adria Cimino)
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual growth rate in the double digits from today over the next several years, with the market reaching ...
In Article Trend: Somewhat-Bullish
April 30, 2025 (00:32) / "Zacks Commentary" (by Shaun Pruitt)
Buy Pfizer ( PFE ) Stock for a Rebound After Crushing Q1 EPS Expectations?
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
In Article Trend: Neutral
April 29, 2025 (17:13) / "CNBC"
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. - his administration's bid to boost manufacturing in the country.
In Article Trend: Somewhat-Bullish
April 29, 2025 (16:10) / "Benzinga" (by Avi Kapoor)
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings - Hims & Hers Health ( NYSE:HIMS ) , Leggett & Platt ( NYSE:LEG )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Tuesday. The Dow traded up 0.70% to 40,507.41 while the NASDAQ rose 0.30% to 17,417.49. The S&P 500 also rose, gaining, 0.37% to 5,548.98. Materials shares jumped by 0.6% on Monday.
In Article Trend: Somewhat-Bullish
April 29, 2025 (15:34) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales
PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.
In Article Trend: Neutral
April 29, 2025 (15:31) / "Benzinga" (by Vandana Singh)
Pfizer's Covid Windfall Shrinks, Expands Cost-Cutting Efforts - Pfizer ( NYSE:PFE )
Pfizer Q1 EPS beat at $0.92 vs. $0.67 estimate, but sales dipped 8% YoY to $13.71 billion, below $13.95 billion forecast. Paxlovid sales plunged 75%, while Vyndaqel jumped 33% and Comirnaty rose 62% YoY in Q1. Don't face extreme market conditions unprepared.
In Article Trend: Neutral
April 29, 2025 (15:11) / "Zacks Commentary" (by Zacks Equity Research)
Economic Data Deluge
A busy day greets us this morning, with major economic news hitting the tape ahead of the normal trading session, during it and afterwards, as well. Pre-market futures are mixed-to-flat once again, this time with the blue-chip Dow leading into positive territory.
In Article Trend: Neutral
April 29, 2025 (14:29) / "Zacks Commentary" (by Mark Vickery)
Trade Balance in Goods Hits All-Time Record, Plus Q1 Earnings
Pre-market futures are mixed-to-flat once again, this time with the blue-chip Dow leading into positive territory.
In Article Trend: Neutral
April 29, 2025 (14:09) / "Benzinga" (by Globe Newswire)
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) ( NASDAQ: CERE ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, April 29, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) CERE for violations of the ...
In Article Trend: Neutral
April 29, 2025 (13:28) / "Zacks Commentary" (by Zacks Equity Research)
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
In Article Trend: Somewhat-Bullish
April 29, 2025 (12:00) / "CNBC"
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 40%
The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
In Article Trend: Neutral
April 29, 2025 (11:55) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Surpasses Q1 Earnings Estimates
Pfizer (PFE) delivered earnings and revenue surprises of 43.75% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
April 29, 2025 (11:45) / "Motley Fool" (by James Brumley)
If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today
Things were going great, right until the point when they weren't.
In Article Trend: Neutral
April 29, 2025 (10:59) / "CNBC"
Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall
The cuts aim to help Pfizer recover from the rapid decline of its Covid business and stock price over the last few years, and appear to be paying off.
In Article Trend: Neutral
April 29, 2025 (10:32) / "Benzinga" (by Vishaal Sanjay)
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week - Apple ( NASDAQ:AAPL ) , AbbVie ( NYSE:ABBV )
U.S. stock futures rose Tuesday morning as investors looked ahead to upcoming earnings reports and awaited greater market clarity throughout the week. Things haven't moved all that much on the trade and tariffs front, with Treasury Secretary Scott Bessent merely stating on Monday that it was up ...
In Article Trend: Neutral
April 29, 2025 (10:32) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron
Pfizer, Eli Lilly, Amgen, Biogen and Regeneron are included in this Analyst Blog.
In Article Trend: Neutral
April 29, 2025 (07:57) / "Benzinga" (by Tanya Rawat)
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
The President Donald Trump administration's request for Novavax Inc. NVAX to conduct new clinical trials for its COVID-19 vaccine.
In Article Trend: Somewhat-Bullish
April 29, 2025 (06:45) / "Benzinga" (by Avi Kapoor)
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Guardant Health ( NASDAQ:GH ) , Pfizer ( NYSE:PFE )
Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29. Analysts expect the New York-based company to report quarterly earnings at 68 cents per share, down from 82 cents per share in the year-ago period.
In Article Trend: Somewhat-Bullish
April 28, 2025 (20:50) / "Benzinga" (by Globe Newswire)
ROSEN, A LEADING LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, April 28, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.
In Article Trend: Somewhat-Bullish
April 28, 2025 (16:08) / "Zacks Commentary" (by Zacks Equity Research)
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
In Article Trend: Neutral
April 28, 2025 (14:00) / "Benzinga" (by PRNewswire)
ELLIS ISLAND HONORS SOCIETY ANNOUNCES THE 2025 ELLIS ISLAND MEDALS OF HONOR RECIPIENTS
Leaders in business, education, entertainment, public service, philanthropy, media, healthcare, sports, and the defense of the United States to be honored with the prestigious Ellis Island Medals of Honor on May 10th During Gala on Ellis Island
In Article Trend: Bullish
April 28, 2025 (13:18) / "Zacks Commentary" (by Ekta Bagri)
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.
In Article Trend: Somewhat-Bullish
April 28, 2025 (12:17) / "Zacks Commentary" (by Sumit Singh)
4 Top Value Stocks to Invest in as US-Global Trade Talks Unfold
Value investing is essentially about selecting cheap but fundamentally sound stocks. STNE, CSV, ASB & PFE boast low P/CF ratios.
In Article Trend: Somewhat-Bullish
April 28, 2025 (11:47) / "Motley Fool" (by Keith Speights)
3 Dividend Stocks to Buy and Hold for the Next Decade
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the ...
In Article Trend: Bullish
April 28, 2025 (11:00) / "Benzinga" (by Globe Newswire)
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research ( AACR ) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax - Ascentage Pharma Group ( NASDAQ:AAPG )
ROCKVILLE, Md. and SUZHOU, China, April 28, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma AAPG HKEX: 6855 ) ) , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today ...
In Article Trend: Neutral
April 28, 2025 (10:21) / "Motley Fool" (by Eric Volkman)
Down 36%, Is Moderna a Buy on the Dip?
In many ways, the pandemic is becoming a faded memory. With that, a major pandemic star -- biotech Moderna ( NASDAQ: MRNA ) -- also seems to be disappearing from the world's attention. The company's stock is down a headache-inducing 36% year to date, compared to the S&P 500 index's mere 9% ...
In Article Trend: Somewhat-Bullish
April 28, 2025 (09:59) / "Zacks Commentary" (by Zacks Equity Research)
Microsoft, Meta Platform, Apple, Amazon and Alphabet are part of Zacks Earnings Preview
Chicago, IL - April 28, 2025 - Zacks.com releases the list of companies likely to issue earnings surprises. This week's list includes Microsoft ( MSFT Quick QuoteMSFT - ) , Meta Platform ( META Quick QuoteMETA - ) , Apple ( AAPL Quick QuoteAAPL - ) , Amazon ( AMZN Quick QuoteAMZN - ) and Alphabet ...
In Article Trend: Neutral
April 28, 2025 (08:48) / "Motley Fool" (by Keith Speights)
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Getting dizzy from the stock market's gyrations? Join the club. The major market indexes are behaving like a frantic yo-yo, swinging up or down depending on the latest tariff- or Fed-related news from the White House.Some investors might be tempted to throw in the towel on stocks altogether until ...
In Article Trend: Somewhat-Bullish
April 26, 2025 (18:32) / "Motley Fool" (by Justin Pope)
1 Superstar Dividend Growth Stock to Buy if the Market Crashes
Investors have been waiting nearly a decade to score a good deal on this healthcare star.
In Article Trend: Neutral
April 26, 2025 (17:10) / "GlobeNewswire" (by VALNEVA)
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Saint Herblain ( France ) , April 26, 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité de Santé ( HAS ) , has updated its recommendation for use of Valneva's single-dose ...
In Article Trend: Neutral
April 26, 2025 (17:10) / "Benzinga" (by Globe Newswire)
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Saint Herblain ( France ) , April 26, 2025 - Valneva SE VALNVLA, a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité de Santé ( HAS ) , has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ® for the ...
In Article Trend: Neutral
April 26, 2025 (13:50) / "Benzinga" (by Globe Newswire)
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options
In Article Trend: Neutral
April 25, 2025 (21:19) / "Zacks Commentary" (by Sheraz Mian)
Mag 7 Earnings Preview: What Can Investors Expect?
We get into the heart of the Q1 earnings season this week, with more than 800 companies reporting results, including four Magnificent 7 members and 173 other S&P 500 members. How are expectations shaping up?
In Article Trend: Neutral
April 25, 2025 (20:19) / "Benzinga" (by Globe Newswire)
ROSEN, A TOP RANKED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, April 25, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.
In Article Trend: Somewhat-Bullish
April 25, 2025 (17:00) / "GlobeNewswire" (by Nurix Therapeutics)
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour ...
In Article Trend: Neutral
April 25, 2025 (15:57) / "Zacks Commentary" (by Zacks Equity Research)
Can Moderna Keep the Beat Streak Alive This Earnings Season?
When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.
In Article Trend: Neutral
April 25, 2025 (15:56) / "Benzinga" (by Globe Newswire)
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) ( NASDAQ: CERE ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
NEW YORK, April 25, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) CERE for violations of the ...
In Article Trend: Neutral
April 25, 2025 (12:13) / "Zacks Commentary" (by Zacks Equity Research)
5 Top Vanguard Mutual Funds to Buy Amid Volatile Market Conditions
Invest in Vanguard mutual funds like VGENX, VQNPX, VEIPX, VASVX and VWNDX, to earn excellent returns amid uncertain market conditions.
In Article Trend: Somewhat-Bullish
April 25, 2025 (12:08) / "Benzinga" (by Globe Newswire)
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders - Cogent Biosciences ( NASDAQ:COGT )
WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc.
In Article Trend: Neutral
April 25, 2025 (12:08) / "GlobeNewswire" (by Cogent Biosciences)
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from four pipeline programs during poster ...
In Article Trend: Neutral
April 25, 2025 (11:06) / "Zacks Commentary" (by Zacks Equity Research)
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
In Article Trend: Neutral
April 24, 2025 (19:36) / "Benzinga" (by Vandana Singh)
Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform - Guardant Health ( NASDAQ:GH ) , Pfizer ( NYSE:PFE )
Guardant and Pfizer will use liquid biopsy tests in global oncology clinical trials, including monitoring ctDNA as a therapy response marker Pfizer gains access to Guardant's testing capabilities in China through an existing partnership with Adicon Holdings. Feel unsure about the market's next ...
In Article Trend: Neutral
April 24, 2025 (15:54) / "Zacks Commentary" (by Zacks Equity Research)
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
In Article Trend: Neutral
April 24, 2025 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
PFE vs. LLY: Which Stock Is the Better Value Option?
In Article Trend: Bullish
April 24, 2025 (14:08) / "Benzinga" (by Globe Newswire)
Pharmaceutical Market Size is projected to reach US$ 2.84 billion by 2031 at 7.1% CAGR - The Insight Partners
US & Canada, April 24, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the pharmaceutical market is observing significant growth owing to the increasing disease burden worldwide and surging demand for innovative treatments.
In Article Trend: Somewhat-Bullish
April 24, 2025 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 24, 2025 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Are Investors Undervaluing Pfizer ( PFE ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In Article Trend: Bullish
April 24, 2025 (13:15) / "Zacks Commentary" (by Zacks Equity Research)
Curious about Pfizer ( PFE ) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
In Article Trend: Somewhat-Bullish
April 24, 2025 (12:30) / "Motley Fool" (by George Budwell)
5 All-Weather Dividend Stocks to Buy Right Now
Market uncertainty has become the defining characteristic of the 2025 investment landscape. Thanks to volatile trade policies, persistent inflation concerns, and geopolitical tensions, investors are facing a challenging environment that demands both defensive positioning and growth potential.
In Article Trend: Bullish
April 24, 2025 (11:59) / "Zacks Commentary" (by Zacks Equity Research)
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.
In Article Trend: Neutral
April 24, 2025 (11:01) / "CNBC"
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump's planned pharmaceutical tariffs.
In Article Trend: Neutral
April 24, 2025 (10:45) / "Motley Fool" (by Prosper Junior Bakiny)
2 No-Brainer Stocks to Buy With Less Than $30
Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. Even with a relatively modest sum, like $30, it's possible to acquire one whole share of a top corporation that's likely to perform well in the long run.
In Article Trend: Somewhat-Bullish
April 24, 2025 (10:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
MAINZ, Germany, April 24, 2025 -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association ...
In Article Trend: Neutral
April 24, 2025 (08:51) / "Motley Fool" (by Keith Speights)
Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?
Going against the grain often works in investing. Several of the most successful investors are contrarians by nature. One popular investing strategy -- the "Dogs of the Dow" -- focuses on buying the 10 stocks in the Dow Jones Industrial Average ( DJINDICES: ^DJI ) with the highest dividend yields.
In Article Trend: Neutral
April 23, 2025 (23:00) / "Benzinga" (by Globe Newswire)
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin - Ascentage Pharma Group ( NASDAQ:AAPG )
ROCKVILLE, Md. and SUZHOU, China, April 23, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma AAPG HKEX: 6855 ) ) , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today ...
In Article Trend: Neutral
April 23, 2025 (23:00) / "GlobeNewswire" (by ASCENTAGE PHARMA GROUP INTERNATIONAL)
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
ROCKVILLE, Md. and SUZHOU, China, April 23, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma ( NASDAQ: AAPG. HKEX: 6855 ) , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological ...
In Article Trend: Neutral
April 23, 2025 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Stock Sinks As Market Gains: What You Should Know
In the closing of the recent trading day, Pfizer (PFE) stood at $22.36, denoting a -0.78% change from the preceding trading day.
In Article Trend: Neutral
April 23, 2025 (21:00) / "Benzinga" (by Vandana Singh)
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps - Novavax ( NASDAQ:NVAX )
Novavax says its COVID-19 vaccine BLA is approvable and awaits FDA response after a post-marketing data request. SHIELD-Utah study shows Novavax's JN.1 vaccine had milder side effects than Pfizer-BioNTech's 2024-2025 mRNA shot. Markets are messy-but the right setups can still deliver ...
In Article Trend: Somewhat-Bullish
April 23, 2025 (19:47) / "Benzinga" (by Vandana Singh)
Why Is Summit Therapeutics Stock Soaring On Wednesday? - Summit Therapeutics ( NASDAQ:SMMT )
Ivonescimab plus chemo significantly improved PFS over tislelizumab combo in Phase 3 NSCLC trial, meeting primary endpoint. No new safety signals were reported in the HARMONi-6 trial; full data to be shared at a major medical conference this year.
In Article Trend: Somewhat-Bullish
April 23, 2025 (17:37) / "Zacks Commentary" (by Zacks Investment Research)
PayPal is Trading Dirty Cheap at 11.86X P/E: Buy or Hold the Stock?
PYPL's cheap valuation, strong portfolio, and expanding clientele make the stock attractive over the long term amid intensifying competition.
In Article Trend: Somewhat-Bullish
April 23, 2025 (16:17) / "CNBC"
Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
Corporations like Target, McDonald's and Delta donated to Trump's inaugural committee after skipping the last two cycles. Now he has roiled their businesses.
In Article Trend: Neutral
April 23, 2025 (14:44) / "GlobeNewswire" (by Arvinas Inc.)
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting
- Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial ...
In Article Trend: Neutral
April 23, 2025 (12:30) / "Motley Fool" (by George Budwell)
2 High-Yield Dividend Stocks to Buy for Passive Income
Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks can do the heavy lifting. The key is focusing on companies with strong yields, reliable payouts, and recession-resistant business models.In today's volatile market, where ...
In Article Trend: Bullish
April 23, 2025 (11:43) / "Benzinga" (by Namrata Sen)
Trump Administration Considers Lowering US Drug Prices To International Levels: Report - iShares U.S. Pharmaceutical ETF ( ARCA:IHE ) , Johnson & Johnson ( NYSE:JNJ )
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. What Happened: The Trump Administration is contemplating a policy to align U.S. drug prices with lower rates in other developed countries.
In Article Trend: Neutral
April 23, 2025 (10:58) / "Zacks Commentary" (by Kinjel Shah)
Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
In Article Trend: Neutral
April 23, 2025 (10:40) / "Motley Fool" (by David Jagielski)
What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?
The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth.Pfizer ( ...
In Article Trend: Somewhat-Bullish
April 23, 2025 (09:07) / "Motley Fool" (by Justin Pope)
Is Eli Lilly Stock a Buy?
The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.
In Article Trend: Somewhat-Bullish
April 23, 2025 (07:51) / "Motley Fool" (by Sean Williams)
S&P 500 Sell-Off: 2 Ultra-High-Yield Dividend Stocks That Make for No-Brainer Buys
Two brand-name, time-tested companies -- sporting an average yield of 7% -- are ripe for the picking amid a historic bout of volatility on Wall Street.
In Article Trend: Somewhat-Bullish
April 22, 2025 (21:37) / "Motley Fool" (by Eric Volkman)
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Vertex Pharmaceuticals ( NASDAQ: VRTX ) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes. That rise was slightly more pronounced than the S&P 500 index's 2.5% ...
In Article Trend: Somewhat-Bullish
April 22, 2025 (17:44) / "CNBC"
Healthy Returns: Trump seeks to change Medicare drug price negotiations in a win for pharma
Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.
In Article Trend: Neutral
April 22, 2025 (16:17) / "Benzinga" (by Globe Newswire)
ROSEN, A LEADING NATIONAL FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, April 22, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics ...
In Article Trend: Somewhat-Bullish
April 22, 2025 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate Pfizer ( PFE ) to Report a Decline in Earnings: What to Look Out for
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 22, 2025 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search Pfizer Inc. ( PFE ) : Here is What You Need to Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
April 22, 2025 (10:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
MAINZ, Germany, April 22, 2025 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT ( 2:00 ...
In Article Trend: Neutral
April 21, 2025 (18:29) / "Benzinga" (by Vandana Singh)
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline - Pfizer ( NYSE:PFE )
BofA cuts Pfizer's Q1 2025 EPS estimate by 4.9% and revenue by 2.1% due to updated assumptions. Pfizer stock trades at 7x expected 2024 earnings, lower than peer average; dividend yield stands at ~8%. Markets are messy-but the right setups can still deliver triple-digit gains.
In Article Trend: Neutral
April 21, 2025 (12:45) / "GlobeNewswire" (by Vaccinex)
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research ( AACR )
Unique mechanism of pepinemab induced abundant, mature TLS, correlating with durable clinical benefit in HNSCC and in neoadjuvant study in melanoma.
In Article Trend: Neutral
April 21, 2025 (12:45) / "Benzinga" (by Globe Newswire)
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research ( AACR ) - Vaccinex ( OTC:VCNX )
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma.
In Article Trend: Neutral
April 21, 2025 (11:00) / "GlobeNewswire" (by ASCENTAGE PHARMA GROUP INTERNATIONAL)
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology ( CSCO ) 2025 Guidelines
ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma ( NASDAQ: AAPG. HKEX: 6855 ) , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological ...
In Article Trend: Somewhat-Bullish
April 20, 2025 (09:45) / "Motley Fool" (by Keith Speights)
3 Ultra-High-Yield Dividend Stocks to Buy Right Now That Are Dirt Cheap
Every cloud has a silver lining. Sometimes, they have two. That's the case with many stocks in the current market downturn. Dividend yields are higher. Valuations are lower. And those are two big pluses for income investors.Some stocks have especially attractive dividend yields and valuations.
In Article Trend: Neutral
April 19, 2025 (14:40) / "Motley Fool" (by Josh Kohn-Lindquist)
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now
The S&P 500 has dropped 10% or more nine times since 2010, not including the current sell-off. However, the index has delivered an average return of 18% in the year following the start date of these corrections. In fact, the market was higher in eight of the last nine instances.Keeping these ...
In Article Trend: Somewhat-Bullish
April 19, 2025 (12:30) / "Motley Fool" (by Dan Victor)
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
It's been a tough start to 2025 for investors amid concerns regarding the strength of the U.S. economy and uncertainties over the effect of sweeping changes in trade policy under the Trump administration. At the time of writing, the S&P 500 index is down about 8% year to date.Yet, periods of ...
In Article Trend: Somewhat-Bullish
April 18, 2025 (21:12) / "Benzinga" (by Globe Newswire)
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, April 18, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics ...
In Article Trend: Somewhat-Bullish
April 18, 2025 (12:15) / "Motley Fool" (by Prosper Junior Bakiny)
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include household names such as Wegovy and Zepbound, two drugs whose sales are rapidly growing.Their success has ...
In Article Trend: Neutral
April 18, 2025 (08:51) / "Motley Fool" (by Keith Speights)
Where Will Eli Lilly Be in 5 Years?
What a difference five years can make. Just look at Eli Lilly ( NYSE: LLY ) . In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer, and Merck boasting larger market caps.
In Article Trend: Somewhat-Bullish
April 18, 2025 (08:00) / "GlobeNewswire" (by VALNEVA)
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Saint Herblain ( France ) , April 18, 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention's ( CDC ) Advisory Committee on Immunization Practices ( ...
In Article Trend: Neutral
April 18, 2025 (08:00) / "Benzinga" (by Globe Newswire)
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Saint Herblain ( France ) , April 18, 2025 - Valneva SE VALNVLA, a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S.
In Article Trend: Neutral
April 18, 2025 (07:05) / "Motley Fool" (by James Brumley)
3 Magnificent S&P 500 Dividend Stocks Down 11% to 63% to Buy and Hold Forever
As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they are.
In Article Trend: Neutral
April 17, 2025 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Laps the Stock Market: Here's Why
Pfizer (PFE) closed the most recent trading day at $22.15, moving +0.48% from the previous trading session.
In Article Trend: Somewhat-Bullish
April 17, 2025 (19:31) / "Benzinga" (by Vandana Singh)
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Moderna ( NASDAQ:MRNA ) , GSK ( NYSE:GSK ) , Pfizer ( NYSE:PFE )
CDC estimates 15K-20K RSV hospitalizations yearly among U.S. adults aged 50-59. RSV causes 42K hospitalizations annually in adults aged 50-64, per U.S. study. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in ...
In Article Trend: Somewhat-Bullish
April 17, 2025 (17:06) / "Zacks Commentary" (by Ekta Bagri)
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
In Article Trend: Somewhat-Bullish
April 17, 2025 (16:58) / "Benzinga" (by Vandana Singh)
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential - Eli Lilly ( NYSE:LLY )
Orforglipron lowered A1C by 1.3%-1.6% from a baseline of 8.0% at 40 weeks. BofA forecasts 2030 orforglipron sales at $10 billion vs. $9 billion consensus estimate. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in ...
In Article Trend: Neutral
April 17, 2025 (16:46) / "Motley Fool" (by Rich Smith)
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.
In Article Trend: Neutral
April 17, 2025 (15:53) / "CNBC"
Brain implant cleared by FDA for Precision Neuroscience, a Musk Neuralink rival
Precision Neuroscience announced that a core component of its brain implant system has been approved by the FDA.
In Article Trend: Somewhat-Bullish
April 17, 2025 (13:20) / "Zacks Commentary" (by Zacks Equity Research)
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.
In Article Trend: Neutral
April 17, 2025 (13:15) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.
In Article Trend: Neutral
April 17, 2025 (12:30) / "Motley Fool" (by Justin Pope)
Is the Schwab U.S. Dividend Equity ETF a Buy Now?
The popular ETF recently underwent a shake-up and declared a whopper of a dividend.
In Article Trend: Somewhat-Bullish
April 17, 2025 (11:58) / "Benzinga" (by Vandana Singh)
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars - Eli Lilly ( NYSE:LLY )
Orforglipron cut A1C by 1.2-1.5% and reduced weight up to 15.8 lbs in adults with type 2 diabetes. Over 65% of high-dose patients reached an A1C of 6.5% or less after 40 weeks of treatment. Feel unsure about the market's next move?
In Article Trend: Neutral
April 17, 2025 (10:00) / "Benzinga" (by Globe Newswire)
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Channel Therapeutics ( AMEX:CHRO )
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™
In Article Trend: Somewhat-Bullish
April 17, 2025 (10:00) / "GlobeNewswire" (by Ligand Pharmaceuticals)
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™
In Article Trend: Somewhat-Bullish
April 17, 2025 (07:51) / "Motley Fool" (by Sean Williams)
Trump Tariff Plunge: 3 Phenomenal Stocks to Buy at Bargain Prices Right Now
Tariff uncertainty has created an ideal opportunity for long-term investors to pounce.
In Article Trend: Somewhat-Bullish
April 16, 2025 (15:45) / "GlobeNewswire" (by VALNEVA)
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
Saint-Herblain ( France ) , April 16, 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025 at the Walter E. convention center in Washington, ...
In Article Trend: Neutral
April 16, 2025 (15:45) / "Benzinga" (by Globe Newswire)
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
Saint-Herblain ( France ) , April 16, 2025 - Valneva SE VALNVLA, a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025 at the Walter E. convention center in Washington, D.C.
In Article Trend: Neutral
April 16, 2025 (13:45) / "Zacks Commentary" (by Kinjel Shah)
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
In Article Trend: Neutral
April 16, 2025 (12:45) / "Benzinga" (by PRNewswire)
TIME Reveals the 2025 TIME100 List of the 100 Most Influential People in the World
TIME to Convene Leaders From the Global TIME100 Community at the 2025 TIME100 Summit on April 23 in NYC Annual TIME100 Gala Recognizing Listmakers to Feature Snoop Dogg as Host with Special Musical Performances from Ed Sheeran and Myles Smith on April 24 in NYC
In Article Trend: Somewhat-Bullish
April 16, 2025 (12:00) / "Benzinga" (by Globe Newswire)
Infinite Reality To Acquire Agentic AI Company Touchcast For $500M In A Deal That Values Infinite Reality At $15.5B
BOCA RATON, Fla., April 16, 2025 ( GLOBE NEWSWIRE ) -- Infinite Reality™ ( iR ) , an innovation company powering the next generation of digital media and ecommerce through extended reality ( XR ) , artificial intelligence ( AI ) , and other immersive technologies, announced today the company has ...
In Article Trend: Bullish
April 15, 2025 (22:53) / "Motley Fool" (by Eric Volkman)
Why Pfizer Stock Topped the Market on Tuesday
On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer ( NYSE: PFE ) . Somewhat counterintuitively, this week's rise came after the company announced it was ending the development of a drug in a very hot product category.
In Article Trend: Neutral
April 15, 2025 (20:13) / "Benzinga" (by Globe Newswire)
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer - Protara Therapeutics ( NASDAQ:TARA )
NEW YORK, April 15, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. TARA, a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer.
In Article Trend: Neutral
April 15, 2025 (20:13) / "GlobeNewswire" (by Protara Therapeutics)
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
NEW YORK, April 15, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. ( Nasdaq: TARA ) , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer.
In Article Trend: Neutral
April 15, 2025 (19:15) / "Benzinga" (by Vandana Singh)
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Novavax ( NASDAQ:NVAX )
Novavax recipients had 1.7 symptoms on average vs. 2.8 for Pfizer-BioNTech in SHIELD-Utah. 24.2% of Novavax recipients had Grade 2+ symptoms vs. 43.8% of Pfizer-BioNTech recipients. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt ...
In Article Trend: Neutral
April 15, 2025 (16:57) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer Halts Obesity Pill Development Amid Safety Concerns
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
In Article Trend: Neutral
April 15, 2025 (14:00) / "Zacks Commentary" (by Ahan Chakraborty)
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
In Article Trend: Somewhat-Bullish
April 15, 2025 (11:39) / "Motley Fool" (by Cory Renauer)
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?
Pfizer ( NYSE: PFE ) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management.
In Article Trend: Neutral
April 15, 2025 (10:30) / "GlobeNewswire" (by Inc.)
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
HUNTSVILLE, AL, April 15, 2025 ( GLOBE NEWSWIRE ) -- Serina Therapeutics, Inc. ( "Serina" ) ( NYSE American: SER ) , a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development ...
In Article Trend: Neutral
April 14, 2025 (21:50) / "GlobeNewswire" (by Applied Therapeutics)
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results
- Appointed John H. Johnson as Executive Chairman. Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. and Reena Thomas Colacot as Vice President and Head of Quality ...
In Article Trend: Somewhat-Bullish
April 14, 2025 (21:33) / "Benzinga" (by Globe Newswire)
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, April 14, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics ...
In Article Trend: Somewhat-Bullish
April 14, 2025 (19:34) / "Benzinga" (by Tim Melvin)
This Strategy Always Outperforms In Bear Markets - Ford Motor ( NYSE:F ) , Capital One Finl ( NYSE:COF )
When the market throws a delightful little soiree for the bears and headlines scream of doom, gloom and capital destruction, it often feels like it's the end of it all. But odds are the world is not going to end. It was the same in previous bear markets.
In Article Trend: Neutral
April 14, 2025 (19:33) / "Benzinga" (by Tim Melvin)
This Strategy Always Outperforms In Bear Markets - Ford Motor ( NYSE:F ) , Capital One Finl ( NYSE:COF )
When the market throws a delightful little soiree for the bears and headlines scream of doom, gloom and capital destruction, it often feels like it's the end of it all. But odds are the world is not going to end. It was the same in previous bear markets.
In Article Trend: Neutral
April 14, 2025 (16:58) / "Benzinga" (by Globe Newswire)
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) ( NASDAQ: CERE ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
NEW YORK, April 14, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) CERE for violations of the ...
In Article Trend: Neutral
April 14, 2025 (15:45) / "GlobeNewswire" (by VALNEVA)
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
Saint Herblain ( France ) , April 14, 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company today announced that the Brazilian Health Regulatory Agency ( ANVISA ) has granted marketing authorization to its single-dose vaccine IXCHIQ® for the prevention of disease ...
In Article Trend: Somewhat-Bullish
April 14, 2025 (15:45) / "Benzinga" (by Globe Newswire)
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
Saint Herblain ( France ) , April 14, 2025 - Valneva SE VALNVLA, a specialty vaccine company today announced that the Brazilian Health Regulatory Agency ( ANVISA ) has granted marketing authorization to its single-dose vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus ...
In Article Trend: Somewhat-Bullish
April 14, 2025 (15:12) / "Motley Fool" (by Rich Smith)
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Pfizer bows, but is not entirely out of the GLP-1 race.
In Article Trend: Neutral
April 14, 2025 (14:49) / "Benzinga" (by Vandana Singh)
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? - Viking Therapeutics ( NASDAQ:VKTX ) , Structure Therapeutics ( NASDAQ:GPCR )
Roche's CT-996 showed 6.1% mean weight loss in just 4 weeks in obese patients without type 2 diabetes. Structure Therapeutics' GSBR-1290 cut weight by 6.2% over 12 weeks in its Phase 2a obesity trial. Feel unsure about the market's next move?
In Article Trend: Neutral
April 14, 2025 (14:13) / "Benzinga" (by Vandana Singh)
Pfizer Discontinues Once-Daily Weight Loss Pill Over Liver Injury In One Patient - Pfizer ( NYSE:PFE )
Danuglipron trials involved over 1,400 participants before discontinuation. One asymptomatic liver injury case noted in dose-optimization study. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile markets.
In Article Trend: Neutral
April 14, 2025 (10:45) / "CNBC"
Pfizer scraps daily weight loss pill after liver injury in one patient
The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of the booming market for GLP-1s.
In Article Trend: Neutral
